Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Expanded indications for Januvia

Executive Summary

Merck's type 2 diabetes agent is approved as first-line therapy in combination with metformin and as an add-on to a sulfonylurea or sulfonylurea and metformin combination regimen, Merck says Oct. 17. Januvia (sitagliptin), the only marketed DPP-4 inhibitor, is indicated for improvement of glycemic control in adults with type 2 diabetes (1"The Pink Sheet" Oct. 23, 2006, p. 6). Labeling is also updated to include hypersensitivity reactions - including anaphylaxis, angioedema and exfoliative skin conditions - in the Warnings and Precautions sections...

You may also be interested in...

Januvia Clears FDA; Sitagliptin Has “Neutral Effects” On Weight, Agency Says

Merck's dipeptidyl peptidase IV inhibitor Januvia has no significant effect on weight, FDA said after approving sitagliptin for type 2 diabetes Oct. 16

Cipla's Advair Generic Debut In Sight, More Platform Deals On Radar Post Ethris

Cipla believes it is “pretty close” to approval for its Advair generic in the US, while another product, generic Abraxane, stands delayed currently. Following the deal with Ethris, which is progressing inhaled mRNA-based therapies, the company signals interest in platforms such as CAR-T as well.

Inside US FDA’s Return To In-Person Meetings

In an interview, OND Deputy Director of Operations Kevin Bugin describes how FDA might be able to "accelerate" the transition back to in-person meetings if the initial phase with Type A and BPD Type 1 meetings goes well. But there is still no plan to return to in-person advisory committees.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts